European Pharmaceutical Reimbursement & Market Access Conference

Optimizing Reimbursement and Market Access for New Pharmaceutical Therapies through a Greater Understanding of the Nuances in Regional Reimbursement, Changes in Global Health Policy and the Critical Importance of Cost-Effectiveness Data

March 8-9, 2010

London

 

As pharmaceutical companies across Europe continue to strive toward full market access for their new therapies, they are encountering more and more challenges in securing adequate funding and reimbursement for their products. Healthcare payers, governments and consumers are all concerned with the escalating cost of pharmaceutical therapies and are striving to ensure that products are not only safe and effective, but also cost-conscious. This is resulting in pharmaceutical and biotech companies rethinking their traditional market access strategies to now include much more detailed and randomized clinical data to support their product effectiveness and efficiency claims. Changes in the regulations and health policy of all countries in Europe is a tremendous challenge for the industry and will be addressed during this conference, which will highlight many of the hurdles that companies face in bringing their new therapeutics to patients.Creating a unified structure to support reimbursement and market access

 

Topics to be included

• HTA Panel Discussion: Working towards a harmonized structure in Europe
• Regional case studies highlighting nuances in all major markets
• Understanding the importance of a global pricing strategy
• Regulations and legal considerations in reimbursement
• Recognizing the critical importance of clinical data in pharmaceutical funding
• Impact of health care reform on the pharmaceutical industry
• Development of strategic drug pricing campaigns
• Overcoming the increasing threats from generic competition
• Understanding processes for payment from private payers
• Optimizing payment through early-decision making in R&D
• Recognizing the global context of comparative effectiveness
• Evidence threshold requirements for payment: private & public
• Bringing together health economics, market access & reimbursement
• Addressing the impact of potential third party comparative effectiveness studies
• Recent litigation related to pricing and reimbursement
• Designing clinical studies to support reimbursement efforts
• Quality of life and health economics indicators
• Strategies to maintain competitive edge in the industry

 

 

To request the full conference agenda, registration details, and information on promotional pricing please contact:

 

Paul Hernandez, Marketing Manager
phernandez@Q1productions.com
312-602-9684